Abstract
Background Epidemiological studies have reported conflicting findings on the potential adverse effects of long-term antihypertensive medication use on cancer risk. Naturally occurring variation in genes encoding antihypertensive drug targets can be used as proxies for these targets to examine the effect of their long-term therapeutic inhibition on disease outcomes.
Methods Single-nucleotide polymorphisms (SNPs) in ACE, ADRB1, and SLC12A3 associated (P < 5.0 x 10-8) with systolic blood pressure in genome-wide association studies (GWAS) were used to proxy inhibition of angiotensin-converting enzyme (ACE), β-1 adrenergic receptor (ADRB1), and sodium-chloride symporter (NCC), respectively. Summary genetic association estimates for these SNPs were obtained from GWAS consortia for the following cancers: breast (122,977 cases, 105,974 controls), colorectal (58,221 cases, 67,694 controls), lung (29,266 cases, 56,450 controls), and prostate (79,148 cases, 61,106 controls). Replication analyses were performed in the FinnGen consortium (1,573 colorectal cancer cases, 120,006 controls). Inverse-variance weighted random- effects models were used to examine associations between genetically-proxied inhibition of these drug targets and risk of cancer. Multivariable Mendelian randomization and colocalisation analyses were employed to examine robustness of findings to violations of Mendelian randomization assumptions.
Results Genetically-proxied ACE inhibition equivalent to a 1 mmHg reduction in systolic blood pressure was associated with increased odds of colorectal cancer (OR 1.13, 95% CI 1.06-1.22; P = 3.6 x 10-4). This finding was replicated in the FinnGen consortium (OR 1.40, 95% CI 1.02-1.92; P = 0.035). There was little evidence of association of genetically-proxied ACE inhibition with risk of breast cancer (OR 0.98, 95% CI 0.94-1.02, P = 0.35), lung cancer (OR 1.01, 95% CI 0.92-1.10; P = 0.93), or prostate cancer (OR 1.06, 95% CI 0.99-1.13; P = 0.08). Genetically-proxied inhibition of ADRB1 and NCC were not associated with risk of these cancers.
Conclusion Genetically-proxied long-term ACE inhibition was associated with an increased risk of colorectal cancer, warranting comprehensive evaluation of the safety profiles of ACE inhibitors in clinical trials with adequate follow-up. There was little evidence to support associations across other drug target-cancer risk analyses, consistent with findings from short-term randomised controlled trials for these medications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JY is supported by a Cancer Research UK Population Research Postdoctoral Fellowship (C68933/A28534). JY, EEV, VT, GDS, and RMM are supported by Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). JY, TGR, VMW, EEV, VT, GDS, and RMM are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol which is supported by the Medical Research Council (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/6, and MC_UU_00011/4) and the University of Bristol. RMM is also supported by the NIHR Bristol Biomedical Research Centre which is funded by the NIHR and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. EEV is supported by Diabetes UK (17/0005587) and the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). MOS received a post-doctoral fellowship from the Spanish Association Against Cancer (AECC) Scientific Foundation. VDO, MOS, and VM are part of the group 55 of CIBERESP and AGAUR 2017SGR723. CIA is a Cancer Prevention Research Institute of Texas Research Scholar and is supported by RR170048. INTEGRAL-ILCCO is supported by a National Institutes of Health grant (U19 CA203654). The International Lung Cancer Consortium is supported by a National Cancer Institute grant (U19CA203654). GC is supported by R01 NIH/NCI CA143237 and CA204279. Consortia-specific funding is presented in the Main Text.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies contributing data to these analyses had the relevant institutional review board approval from each country, in accordance with the Declaration of Helsinki, and all participants provided informed consent. Approval was received to use restricted summary genetic association data from GECCO, INTEGRAL ILCCO, and PRACTICAL consortia (App 345) after submitting a proposal to access this data (consortia contacts to confirm application: kafdem{at}fredhutch.org (GECCO), rayjean.hung{at}lunenfeld.ca (INTEGRAL ILCCO), practical{at}icr.ac.uk (PRACTICAL)). Ethics approval obtained from individual studies contributing to these GWAS consortia is as follows (as presented in the original publications): "All participants provided written informed consent, and each study was approved by the relevant research ethics committee or institutional review board." (GECCO data: Huyghe et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet 51, 2019. https://doi.org/10.1038/s41588-018-0286-6), "All participants in this study signed an informed consent, approved by the local internal review board or ethics committee and administered by trained personnel. The participating studies are individually described in the Supplementary Note." (INTEGRAL ILCCO data: McKay J et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet 49, 2017. https://doi.org/10.1038/ng.3892), "All studies were approved by the appropriate ethics committees (as described in the references for each study listed in Supplementary Table 1), and informed consent was obtained from all participants." (PRACTICAL: Schumacher FR et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet 50, 2018. https://doi.org/10.1038/s41588-018-0142-8)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Members from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium are provided in Supplementary Material. Information on the consortium can be found at http://practical.icr.ac.uk/.
Data Availability
This analysis used both restricted and publicly-available summary genetic association data. Further information on applying to access restricted data from this analysis can be obtained by visiting the following websites: GECCO (https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-gecco.html), INTEGRAL-ILCCO (https://ilcco.iarc.fr/) and PRACTICAL (http://practical.icr.ac.uk/blog/).
